Evidence review

Tesamorelin for Chemotherapy-Induced Neuropathy: What the Data Show

Posted Jun 29, 2026 · Updated Jul 17, 2026 · 3 min read

What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why Tesamorelin might help you

You are reading about Chemotherapy-induced neuropathy (CIPN) — what breaks down matters before any compound name.
Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.

Why Gabapentin / pregabalin matters for you

Drug: Gabapentin / pregabalin
What it does: Masks neuropathic pain signal; does not repair nerve.
Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

Tesamorelin → GH axis / visceral fat

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

Scientific sources catalogued (PubMed, trials, reviews): 4
Claims tagged human evidence: 3
Claims tagged preclinical (animal/lab): 0
Claims tagged anecdotal: 1
Reddit posts catalogued: 0
X posts catalogued: 0
Other anecdote sources (YouTube, Instagram, etc.): 0
Total sources in chain: 4

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.48 / 1.00 — low–moderate — mostly preclinical

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury (source s1)

Phase 2 trial for peripheral nerve injury recovery; no CIPN arm.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Phase 2 trial for peripheral nerve injury recovery; no CIPN arm.

2026-06-29 23:24s1 · #ad50d08ba5c8

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury (source s2)

Describes mechanism hypothesis via GH axis.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Describes mechanism hypothesis via GH axis.

2026-06-29 23:24s2 · #037aef4281f0

Chemotherapy-Induced Peripheral Neuropathy (source s3)

Notes symptomatic management options including gabapentinoids.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Chemotherapy-Induced Peripheral Neuropathy

Notes symptomatic management options including gabapentinoids.

2026-06-29 23:24s3 · #cdb1356edc66

Carpal Tunnel Syndrome Attributed to Medication Use (source s4)

Adverse event reporting association.

Evidence type: Published research.

PubMed.gov

Study

Carpal Tunnel Syndrome Attributed to Medication Use

Adverse event reporting association.

2026-06-29 23:24s4 · #b0ef84552c38

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Evidence · 4 sources · swipe →chain b0ef84552c38 · verify chain · provenance

1 / 4

PubMed.gov

Study

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Phase 2 trial for peripheral nerve injury recovery; no CIPN arm.

2026-06-29 23:24s1 · #ad50d08ba5c8

PubMed.gov

Study

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Describes mechanism hypothesis via GH axis.

2026-06-29 23:24s2 · #037aef4281f0

PubMed.gov

Study

Chemotherapy-Induced Peripheral Neuropathy

Notes symptomatic management options including gabapentinoids.

2026-06-29 23:24s3 · #cdb1356edc66

PubMed.gov

Study

Carpal Tunnel Syndrome Attributed to Medication Use

Adverse event reporting association.

2026-06-29 23:24s4 · #b0ef84552c38

Evidence ledger 5 · tier-ranked · API

humanlow confidence

No published human trials test Tesamorelin for CIPN.

sources: s1

humanlow confidence

Ongoing Phase 2 trial (NCT03150511) tests Tesamorelin after peripheral nerve injury repair for motor/sensory recovery.

sources: s2, s1

humanlow confidence

Gabapentin/pregabalin show modest pain reduction in CIPN human trials.

sources: s3

mechanisticlow confidence

Tesamorelin raises GH and IGF-1, which support axon regeneration in preclinical nerve injury models.

sources: s2

anecdotallow confidence

FAERS data associate Tesamorelin with increased carpal tunnel reports.

sources: s4

Model review1 contributions · 1 modelExpand the recursive review layer

1 / 1

grok/grok-4.3writer

redraft2026-06-29 23:24

Tesamorelin for Chemotherapy-Induced Neuropathy: What the Data Show · 5 claims · 4 sources

inspect — what it was prompted & output

prompted with

(default writer prompt)

input: Write a data-first, evidence-graded article: Tesamorelin for Chemo Neuropathy
Slug: tesamorelin-chemo-neuropathy
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_cross","condition":"Chemotherapy-induced neuropathy (CIPN)","condition_key":"chemo-neuropathy","primary_peptide":"tesamorelin","peptides_in_scope":[{"id":"tesamorelin","name":"Tesamorelin"}],"drugs_in_scope":["gabapentin-lyrica"],"weight_sensitive":false,"stimul

it output

{
  "slug": "tesamorelin-chemo-neuropathy",
  "title": "Tesamorelin for Chemotherapy-Induced Neuropathy: What the Data Show",
  "body": "## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\n\nChemotherapy agents damage peripheral nerves. Platinum drugs, taxanes, and vinca alkaloids hit sensory axons first. This leads to axon degeneration, myelin sheath disruption, and slowed nerve conduction. Inflammation and oxidative stress add layers. Symptoms often include numbness, tingling, pain, and balance issues that can persist or worsen after treatment ends (coasting effect). The core issue is repair lagging behind ongoing degeneration. No single drug repairs the nerve; most options address symptoms only.\n\n## Why Tesamorelin might help you\n\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\n2. **Therefore for you:** If the GH/IGF-1 axis and tissue repair pathways are part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin stimulates growth hormone release. Higher GH can raise IGF-1 levels. IGF-1 supports axon growth and Schwann cell function in lab models. If your neuropathy involves stalled regeneration, this pathway could matter. It does not directly block pain signals.\n\n## Why Gabapentin / pregabalin matters for y

5fc5d17c5d5a3621

Machine verification: /api/articles/tesamorelin-chemo-neuropathy/contributions

Ask this article · 7 suggested prompts

topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "No published human trials test Tesamorelin for CIPN."?

ask tesamorelin-chemo-neuropathy claim c1 · paste includes §SELF

What does the ledger say about this (human tier): "Ongoing Phase 2 trial (NCT03150511) tests Tesamorelin after peripheral nerve injury repair for motor/sensory recovery."?

ask tesamorelin-chemo-neuropathy claim c2 · paste includes §SELF

What does the ledger say about this (human tier): "Gabapentin/pregabalin show modest pain reduction in CIPN human trials."?

ask tesamorelin-chemo-neuropathy claim c3 · paste includes §SELF

What does the ledger say about this (mechanistic tier): "Tesamorelin raises GH and IGF-1, which support axon regeneration in preclinical nerve injury models."?

ask tesamorelin-chemo-neuropathy claim c4 · paste includes §SELF

What does the ledger say about this (anecdotal tier): "FAERS data associate Tesamorelin with increased carpal tunnel reports."?

ask tesamorelin-chemo-neuropathy claim c5 · paste includes §SELF

For my medical situation, what can you answer from your catalogue about Tesamorelin for Chemotherapy-Induced Neuropathy: What the Data Show — and what would you need me to tell you first?

ask tesamorelin-chemo-neuropathy condition gaps · paste includes §SELF

What good and bad outcomes are documented for Tesamorelin for Chemotherapy-Induced Neuropathy: What the Data Show (studies vs anecdotes)?

ask tesamorelin-chemo-neuropathy good bad experiences · paste includes §SELF

What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)

Why Tesamorelin might help you

Why Gabapentin / pregabalin matters for you

How these fit together

What the evidence actually shows

What scientists say

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury (source s1)

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury (source s2)

Chemotherapy-Induced Peripheral Neuropathy (source s3)

Carpal Tunnel Syndrome Attributed to Medication Use (source s4)

Connected articles

Related articles